Roberto Vita1, Salvatore Settineri2, Marco Liotta2, Salvatore Benvenga3, Francesco Trimarchi4. 1. Department of Clinical and Experimental Medicine, University of Messina, Viale Gazzi, 98125 Messina, Italy. Electronic address: rvita@unime.it. 2. Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Viale Gazzi, 98125 Messina, Italy. 3. Department of Clinical and Experimental Medicine, University of Messina, Viale Gazzi, 98125 Messina, Italy; Master Program on Childhood, Adolescent and Women's Endocrine Health, University of Messina, Viale Gazzi, 98125 Messina, Italy; Interdepartmental Program of Molecular & Clinical Endocrinology, and Women's Endocrine Health, University hospital Policlinico Universitario G. Martino, Viale Gazzi, 98125 Messina, Italy. 4. Department of Clinical and Experimental Medicine, University of Messina, Viale Gazzi, 98125 Messina, Italy.
Abstract
OBJECTIVES: Gender identity disorder is defined as a strong and persistent cross-gender identification that is associated with a remarkable uneasiness of living in an incongruent gender (gender dysphoria). We performed a retrospective study on the hormonal and metabolic effects of cross-sex hormone therapy (CSHT) in a small cohort of transgender patients. STUDY DESIGN: Retrospective study. MEAN OUTCOME MEASURES: Hormonal and biochemical parameters at baseline (i.e. before commencement of CSHT) and while on CSHT in 32 patients (21 male to female [MtF], 11 female to male [FtM]) referred to our Endocrinology Unit for gender dysphoria between January 2012 and February 2017. RESULTS: Compared with baseline, in MtF patients systolic blood pressure, red cell count, hemoglobin, hematocrit and total testosterone decreased significantly, while 17-β estradiol and SHBG increased significantly and trendwise significantly, respectively. In FtM patients, total testosterone, red cell count, hemoglobin, hematocrit, creatinine, ɣ-glutamyl transferase and alkaline phosphatase increased significantly, while fasting plasma glucose decreased trendwise significantly. In MtF patients 17-β estradiol correlated positively with SHBG and alkaline phosphatase and negatively with total cholesterol and HDL-c, whereas total testosterone correlated positively with systolic blood pressure, red cell count and hematocrit, and negatively with SHBG. In FtM patients total testosterone correlated positively with creatinine and alkaline phosphatase, while 17-β estradiol correlated positively with HDL-c. CONCLUSIONS: Our data are partly in line with other studies concerning the impact of CSHT on hormonal and metabolic parameters in transgender people. Metabolic changes appear, overall, to be modest, confirming the safety of CSHT.
OBJECTIVES: Gender identity disorder is defined as a strong and persistent cross-gender identification that is associated with a remarkable uneasiness of living in an incongruent gender (gender dysphoria). We performed a retrospective study on the hormonal and metabolic effects of cross-sex hormone therapy (CSHT) in a small cohort of transgender patients. STUDY DESIGN: Retrospective study. MEAN OUTCOME MEASURES: Hormonal and biochemical parameters at baseline (i.e. before commencement of CSHT) and while on CSHT in 32 patients (21 male to female [MtF], 11 female to male [FtM]) referred to our Endocrinology Unit for gender dysphoria between January 2012 and February 2017. RESULTS: Compared with baseline, in MtF patients systolic blood pressure, red cell count, hemoglobin, hematocrit and total testosterone decreased significantly, while 17-β estradiol and SHBG increased significantly and trendwise significantly, respectively. In FtM patients, total testosterone, red cell count, hemoglobin, hematocrit, creatinine, ɣ-glutamyl transferase and alkaline phosphatase increased significantly, while fasting plasma glucose decreased trendwise significantly. In MtF patients 17-β estradiol correlated positively with SHBG and alkaline phosphatase and negatively with total cholesterol and HDL-c, whereas total testosterone correlated positively with systolic blood pressure, red cell count and hematocrit, and negatively with SHBG. In FtM patients total testosterone correlated positively with creatinine and alkaline phosphatase, while 17-β estradiol correlated positively with HDL-c. CONCLUSIONS: Our data are partly in line with other studies concerning the impact of CSHT on hormonal and metabolic parameters in transgender people. Metabolic changes appear, overall, to be modest, confirming the safety of CSHT.
Authors: Rebecca L Taub; Simon Adriane Ellis; Genevieve Neal-Perry; Amalia S Magaret; Sarah W Prager; Elizabeth A Micks Journal: Am J Obstet Gynecol Date: 2020-02-08 Impact factor: 8.661
Authors: Maria-Elisa de Castro-Peraza; Jesús Manuel García-Acosta; Naira Delgado-Rodriguez; Maria Inmaculada Sosa-Alvarez; Rosa Llabrés-Solé; Carla Cardona-Llabrés; Nieves Doria Lorenzo-Rocha Journal: Int J Environ Res Public Health Date: 2019-03-14 Impact factor: 3.390
Authors: Robin Shoemaker; Lisa R Tannock; Wen Su; Ming Gong; Susan B Gurley; Sean E Thatcher; Frederique Yiannikouris; Charles M Ensor; Lisa A Cassis Journal: Biol Sex Differ Date: 2019-09-04 Impact factor: 5.027
Authors: Jesús Manuel García-Acosta; Rosa María San Juan-Valdivia; Alfredo David Fernández-Martínez; Nieves Doria Lorenzo-Rocha; Maria Elisa Castro-Peraza Journal: Int J Environ Res Public Health Date: 2019-12-19 Impact factor: 3.390